PR out this morning:
MIDVALE, Utah--(BW HealthWire)--Feb. 10, 2000--Wasatch
Pharmaceutical, Inc. (OTC BB: WASP), a leader in the research,
development and distribution of dermatological treatments for skin
disorders including acne and psoriasis, today announced that it has
retained OTC Financial Network, a division of National Financial
Communications Corp., to direct its comprehensive shareholder and
investor relations campaign.
"After a decade and a half of research, Wasatch has developed a
line of products and treatments for a wide variety of skin disorders
that constitute a breakthrough in the field of dermatology" stated OTC
Financial Network President Geoffrey Eiten. "The imminent release of
these products and treatments on the open marketplace, combined with
the Company's plan to establish a chain of treatment clinics
nationwide, will drive its dramatic growth over the next 36 months."
The Company reported that it anticipates total net income to
exceed $35 million by fiscal year 2005, the target date for completion
of its chain of 350 treatment centers.
Wasatch Chief Executive Officer, Gary V. Heesch, stated, "As we
prepare for a period of intense and profitable growth, we are excited
to join forces with the professionals at OTC Financial. Their proven
expertise in communicating crucial information to the investment
community will prove of tremendous assistance to Wasatch as we build
our reputation in the pharmaceutical arena."
Wasatch Pharmaceutical, Inc. is a leading research and
development entity in the field of dermatology. The Company targets
its products and treatments to a wide variety of specific
dermatological disease areas, including cystic acne, psoriasis,
eczema, and seborrhea.
OTC Financial Network, a division of National Financial
Communications Corp. of Needham, Massachusetts, is a full-service
financial communications and investor relations firm specializing in
the representation of small-cap companies.
Forward-looking statements in this release are
made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Investors are cautioned that
such forward-looking statements involve risks and uncertainties,
including, without limitation, continued acceptance of the Company's
products, increased levels of competition, new products introduced by
competitors, changes in the rates of subscriber acquisition and
retention, and other risks detailed from time to time in the Company's
periodic reports filed with the Securities and Exchange Commission.
--30--bh/bos*
CONTACT: National Financial Network
Robert Weiss, 781/444-6100 ext.11
or
Wasatch Pharmaceutical, Inc.
Gary V. Heesch, 801/566-9688
|
